ClinicalTrials.gg
RecruitingNCT04448951IMHOTEPUpdated Nov 12, 2026

Immune Homeostasis in Sepsis and Septic Shock

An observational study in Sepsis, Immunologic Paralysis and Immunologic Suppression, sponsored by Charles University, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's title name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Charles University, Czech Republic · Observational

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Shock, Septic with a site in Czechia — 2 open to participants now, 2 under way, none of them phase 3. Shock, Septic · Czechia.

Started
2020
with 1 other
Observational
8 of 19
1 open now
Registered
15th of 19
by date
Lead sponsor
4 of 19
Charles University, Czech Republic

Among the 19 studies in Shock, Septic with a site in Czechia, this one is one of 2 that started in 2020, is one of 8 observational ones, and was the 15th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

2 of the 19 studies in Shock, Septic with a site in Czechia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Shock, Septic with a site in Czechia, or all of them as a file.
02

Study summary

Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.

03

Conditions studied

  • Sepsis
  • Immunologic Paralysis
  • Immunologic Suppression
  • Immune Deficiency

Browse trials for

Keywords

  • sepsis
  • septic shock
  • immune response
  • immunoparalysis
  • transcriptomics
  • flow-cytometry
  • immunomodulation
04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 200 is above the median of 108 across 408 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

sepsis/septic shock according SEPSIS-3 definition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • sepsis/septic shock (SEPSIS-3)
  • age ≥18
  • inclusion within first 24hrs after development/diagnosis of septic shock

Exclusion criteria

Exclusion Criteria:

  • disagreement of the patient or legal representative with the entry into the study
  • patients with primary or secondary immunodeficiency
  • presence of active haematological or an active non-haematological malignancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • sepsis/septic shock

    target population

    Other: transcriptomics · Other: flow-cytometry · Other: cytokines

  • non-septic critically ill

    demographically-matched control group

    Other: transcriptomics · Other: flow-cytometry · Other: cytokines

  • healthy control

    control group

    Other: transcriptomics · Other: flow-cytometry · Other: cytokines

Interventions

  • Othertranscriptomics

    transcriptomics

  • Otherflow-cytometry

    peripheral blood myeloid cells and lymphocytes flow-cytometry

  • Othercytokines

    peripheral blood cytokine analysis

07

What researchers measure

Primary outcomes

  1. Immune response description - flow cytometry

    Detailed description of immune response analyzed by mean of flow cytometry

    Time frame: 2024 - 2026

  2. Immune response description - transcriptomics

    Detailed description of immune response analyzed by mean of transcriptomic analysis

    Time frame: 2024 - 2026

  3. Immune response description - ELISA

    Detailed description of immune response analyzed by mean of ELISA

    Time frame: 2024 - 2026

Secondary outcomes

  1. Diagnostic "immune status" panel

    Diagnostic tool for immune status assessment

    Time frame: 2026 - 2028

08

Study locations

1 of 1 sites recruiting
  • Medical ICU, 1st Dept. of Internal Medicine, Teaching Hospital in Pilsen
    Pilsen, Česká Republika 330 01, Czechia
    Recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2027, 87 months after the start.

Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 87 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2025 → Dec 2027, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 26, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Dec 31, 2027was Aug 2025
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2025→Dec 31, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Aug 31, 2025→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04448951
Responsible party
Thomas Karvunidis (Principal investigator, Charles University, Czech Republic) — Principal investigator
First posted
Jun 26, 2020
Start date
Sep 1, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Thomas Karvunidis, MD, Ph.D.
Contact
karvunidist@fnplzen.cz
+420 377 103 173
Marcela Královcová, MD
Contact
kralovcovam@fnplzen.cz
+420 377 103 173
Thomas Karvunidis, MD, PhD
principal investigator · Carles University Teaching Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion